New Faces In US FDA Review Division Leadership
Executive Summary
Final phase overhaul of FDA's new drug review groups includes half-a-dozen first-time division directors. Most have long experience at the agency – but not all with the drugs they will now oversee.
You may also be interested in...
Ultragenyx CEO: FDA Leaders, Review Divisions Out Of Sync On Accelerated Approval For Gene Therapy
In a Pink Sheet interview Emil Kakkis contends the agency’s recruitment challenges, high turnover rates and a lack of expertise on the diseases for which reviewers are evaluating drugs have created a disconnect between FDA leadership’s stated willingness to permit accelerated approval for gene therapy and what review divisions are doing on the ground.
US FDA Liver Drug Division Acting Director Is Frank Anania
The former Emory professor is now leading the US FDA Division of Hepatology & Nutrition after its inaugural director, Joseph Toerner, moves back to the infectious disease field as acting deputy in FDA’s vaccines office.
US FDA Coronavirus Response Features Three-Step Triage Process For Inquiries
Office of New Drugs Director Peter Stein outlines how his reviewers are prioritizing COVID-19 work, and how he is reallocating resources to the pandemic response.